bpc-157 fda approval status not approved warning The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA's Overreach on Compounded Peptides
Description
Phase 3 protocols often begin at 2mg

doi: 10.1093/ecco-jcc/jjz027
It cant tell us for sure if our tissues have what they need

They might also be at risk of deficiency

The pain relief can last from a few months to a year or more for many